Individualized treatment schedule and investigator ‘s defined time to resistance (TTRi) may prolong survival in patients with metastatic renal cell carcinoma (mRCC)

• DOI: 10.1200/jco.2015.33.15_suppl.e15585
• Publication Date: 2019-03-07T22:21:56Z
• Authors: Manuela Schmidinger; Ursula Vogl; Markus Margreiter; Shahrokh F. Shariat; Christoph Zielinski
• Keywords: Tolerability; Clinical endpoint; Axitinib; Progression-free survival

e15585 Background: Sequential treatment with sunitinib and axitinib was shown to improve survival in mRCC up 33.7 months. Modifying the schedule of (to 2 weeks on-1 week off stead 4 on-2 off) appears tolerability without impairing progression-free (PFS). The aim this analysis investigate outcome an upfront 2/1-schedule real world patients. As RECIST-defined PFS may not always reflect duration clinical benefit daily practice, investigator’s perceived occurrence resistance, defined as time from start resistance perspective (TTRi) used endpoint leading switch Methods: a single centre retrospective conducted evaluate outcomes patients who received first-line on schedule. Sunitinib given at dose 50 mg until (TTRi). Dose escalations were permitted progression continued TTRi Results: 37 consecutive clear cell mRCC-patients included analysis. Most (94%) had ECOG 0 intermediate risk (51%). Ninety-seven percent undergone cytoreductive surgery. most common site metastases lung (73%), followed by lymph nodes (38%), bone (24%) liver (19%). Thirty-two 30% two 3+ metastatic sites. 34.3 months (95%CI: 0.12-71.3). performed 32% At TTRi, offered median number subsequent lines (range 0-5). Strategies beyond mostly (60%), everolimus (53%) sunitinib-rechallenge (53%). overall 75.1 n.r). Conclusions: Individualized scheduling investigator- rather than RECIST-driven sunitinib-treatment dramatically when compared historical data mRCC.